Indian stocks: Visit www.stage2stocks.com →

Fennec Pharmaceuticals Inc.

Stage 2 · Advancing · week 18

As of Oct 22, 2026, Fennec Pharmaceuticals is in Stage 2, the uptrend phase, now in week 18 (since Jun 22, 2026). It closed at $10.32, 19.2% below its 52-week high and above its 200-day average, which is rising.

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. More about the company

$10.32
-0.58% today
$362M · Small cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is FENC early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 13w
S4 27w
S2 24w
S2 18w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 2w → S4 13w → S1 3w → S2 11w → S3 5w → S2 5w → S3 3w → S4 27w → S1 8w → S2 9w → S3 6w → S2 24w → S3 8w → S4 6w → S1 5w → S4 9w → S1 3w → S2 18w current
Total tracked: 165 weeks across 18 stage runs.

FENC among Biotechnology140th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…140FENCStage 2 · wk 1869−1.8%
vs 52W High
-19.2%
$5.77 lo$12.78 hi
19.2% below 52W high, deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 18
1w13w26w
Week 18, proven structure
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
13.2%
200 DMA: $9.12 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.55x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-1.8%
3M
+3.3%
6M
+55.0%
YTD
+34.4%
1Y
+18.3%
Scan Membership
Breakout Watch
Latest: 2025-05-27
10 appearances in last 60 days. First seen: 2019-11-15.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 18 · Vol 0.55x
2026-10-21S2
Wk 18 · Vol 0.35x
2026-10-20S2
Wk 17 · Vol 0.35x
2026-10-19S2
Wk 17 · Vol 0.50x
2026-10-16S2
Wk 17 · Vol 0.63x
2026-10-15S2
Wk 17 · Vol 0.54x
2026-10-14S2
Wk 17 · Vol 1.00x
2026-10-13S2
Wk 16 · Vol 1.13x
2026-10-12S2
Wk 16 · Vol 0.44x
2026-10-09S2
Wk 16 · Vol 0.45x
2026-10-08S2
Wk 16 · Vol 0.42x
2026-10-07S2
Wk 16 · Vol 0.64x
Moving averages & range
50 DMA
$11.09
200 DMA
$9.12
52W High
$12.78
52W Low
$5.77
5D Low
$9.98
Resistance levels (recent highs)
20d High
$10.95
60d High
$12.78
120d High
$12.78
250d High
$12.78
Next resistance
+6.1%
to 20d High
ROE
-18.6%
Profit margin -5.5%
Dividend Yield
0.00%
P/B 8.5

Fennec Pharmaceuticals: quick answers

What stage is Fennec Pharmaceuticals in?

As of Oct 22, 2026, Fennec Pharmaceuticals (FENC) is in Stage 2, the uptrend phase. It entered Stage 2 on Jun 22, 2026 and is in week 18. What the four stages mean

Is Fennec Pharmaceuticals in an uptrend?

Yes. Fennec Pharmaceuticals is in a Stage 2 uptrend. It trades 13.2% above its 200-day average, which is rising.

How far is Fennec Pharmaceuticals from its 52-week high?

Fennec Pharmaceuticals closed at $10.32 on Oct 22, 2026, 19.2% below its 52-week high of $12.78. Its 52-week low is $5.77.

How has Fennec Pharmaceuticals performed over the past year?

As of Oct 22, 2026, Fennec Pharmaceuticals is up 18.3% over the past year and up 34.4% so far in 2026.

Which sector and industry is Fennec Pharmaceuticals in?

Fennec Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.